Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations
In conclusion, although there was high overall agreement between the EMA and HTA organizations about whether alternative treatments exist, there were differences in the types of treatment considered. Parallel joint scientific consultations could inform drug developers about relevant alternative treatments to facilitate patient access to innovative drugs.PMID:38505926 | DOI:10.1002/cpt.3252
Source: Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Jorge Madrid Paredes Jan-Willem Versteeg Rick A Vreman Lourens T Bloem Source Type: research
More News: Drugs & Pharmacology | European Medicines Agency (EMA) | France Health | Germany Health | Italy Health | Netherlands Health | Spain Health | Study | Vaccines | Wales Health